Cencora Aktie News

Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make it attractive for conservative, long-term investors. Recent earnings showed double-digit profit growth, robust revenue from specialty drugs, and high predictability, supporting management's optimi...

Cencora, Inc. ( COR ) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director James Cleary - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michae...

Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations.

The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution network in the United States. The investments — headlined by the opening of its second national distribution center in Ohio and an expanded presence in Alabama and California — will increase Cencora'...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September...

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with only three of 19 companies announcing double-digit percentage boosts in October. November brings a larger chance of 10%+ increases from several companies, including industrials Roper Technologies an...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision ...